| pubmed-article:20634069 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20634069 | lifeskim:mentions | umls-concept:C0031164 | lld:lifeskim |
| pubmed-article:20634069 | lifeskim:mentions | umls-concept:C0038477 | lld:lifeskim |
| pubmed-article:20634069 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:20634069 | lifeskim:mentions | umls-concept:C1272745 | lld:lifeskim |
| pubmed-article:20634069 | pubmed:issue | 16 | lld:pubmed |
| pubmed-article:20634069 | pubmed:dateCreated | 2010-7-27 | lld:pubmed |
| pubmed-article:20634069 | pubmed:abstractText | Herein we describe further evolution of hydroxyethylamine inhibitors of BACE-1 with enhanced permeability characteristics necessary for CNS penetration. Variation at the P2' position of the inhibitor with more polar substituents led to compounds 19 and 32, which retained the potency of more lipophilic analog 1 but with much higher observed passive permeability in MDCK cellular assay. | lld:pubmed |
| pubmed-article:20634069 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20634069 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20634069 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20634069 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20634069 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20634069 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20634069 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20634069 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20634069 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20634069 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20634069 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20634069 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:20634069 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:NauRR | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:QuinnKevin... | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:TungJay SJS | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:HomRoy KRK | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:SinhaSukantoS | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:JohnVargheseV | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:ShamHing LHL | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:TuckerJohn... | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:SauerJohn-Mic... | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:ArtisDean RDR | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:BovaMichael... | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:TruongAnh PAP | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:YaoNanhuaN | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:PleissMichael... | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:RuslimLanyL | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:YednockTed... | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:ProbstGary... | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:KonradiAndrei... | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:BrechtEricE | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:DappenMichael... | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:BrogleyLouisL | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:ZmolekWesW | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:AquinoJoseJ | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:SealyJennifer... | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:FangLarryL | lld:pubmed |
| pubmed-article:20634069 | pubmed:author | pubmed-author:TóthGergleyG | lld:pubmed |
| pubmed-article:20634069 | pubmed:copyrightInfo | 2010 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:20634069 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20634069 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:20634069 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:20634069 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20634069 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20634069 | pubmed:pagination | 4789-94 | lld:pubmed |
| pubmed-article:20634069 | pubmed:meshHeading | pubmed-meshheading:20634069... | lld:pubmed |
| pubmed-article:20634069 | pubmed:meshHeading | pubmed-meshheading:20634069... | lld:pubmed |
| pubmed-article:20634069 | pubmed:meshHeading | pubmed-meshheading:20634069... | lld:pubmed |
| pubmed-article:20634069 | pubmed:meshHeading | pubmed-meshheading:20634069... | lld:pubmed |
| pubmed-article:20634069 | pubmed:meshHeading | pubmed-meshheading:20634069... | lld:pubmed |
| pubmed-article:20634069 | pubmed:meshHeading | pubmed-meshheading:20634069... | lld:pubmed |
| pubmed-article:20634069 | pubmed:meshHeading | pubmed-meshheading:20634069... | lld:pubmed |
| pubmed-article:20634069 | pubmed:meshHeading | pubmed-meshheading:20634069... | lld:pubmed |
| pubmed-article:20634069 | pubmed:meshHeading | pubmed-meshheading:20634069... | lld:pubmed |
| pubmed-article:20634069 | pubmed:meshHeading | pubmed-meshheading:20634069... | lld:pubmed |
| pubmed-article:20634069 | pubmed:meshHeading | pubmed-meshheading:20634069... | lld:pubmed |
| pubmed-article:20634069 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20634069 | pubmed:articleTitle | Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. | lld:pubmed |
| pubmed-article:20634069 | pubmed:affiliation | Department of Medicinal Chemistry, Elan Pharmaceuticals, 180 Oyster Point Boulevard, South San Francisco, CA 94080, United States. | lld:pubmed |
| pubmed-article:20634069 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:20634069 | lld:chembl |
